Vaccines
The George Washington University (GW) is participating in a clinical trial for an investigational COVID-19 vaccine, as part of the COVID-19 Prevention Network established by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The university will serve as a trial site for
Vaccines
Chimpanzees, in the form of a cold virus engineered to carry a piece of the COVID-19 virus, are at the forefront of a novel approach to developing a coronavirus vaccine. The AstraZeneca-Oxford University vaccine, dubbed ChAdOx1 nCoV-19 (AZD1222), is set to begin Phase III trials in Palm Beach County, with
Vaccines
Amid India's growing COVID-19 caseload, with over 1.91 million cases recorded, the country has accelerated its vaccine development efforts. Two homegrown vaccines, Covaxin and ZyCoV-D, have been granted permission to start phase II of their experimental vaccine trials. This development comes just three weeks after these vaccines
Vaccines
Moderna, a Cambridge-based biotechnology company, has commenced the Phase 3 clinical trial of its coronavirus vaccine candidate, mRNA-1273, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services. The
Vaccines
Scientists at the George Washington University (GW) have been selected to participate in a clinical trial for an experimental COVID-19 vaccine, aiming to develop new tools to prevent the disease caused by the novel coronavirus. The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the
Vaccines
Results from a Phase I/II trial published in The Lancet indicate that Oxford University's COVID-19 vaccine, ChAdOx1 nCoV-19, also known as AZD1222, has shown no early safety concerns and induced strong immune responses in both parts of the immune system. The vaccine provoked a T cell response
Vaccines
Generex Biotechnology Corporation, a leading healthcare company, has submitted a pre-IND briefing package to the FDA requesting regulatory guidance on the Phase I/II clinical trial protocol and clinical development plan for its Ii-Key-SARS-CoV-2 coronavirus prophylactic vaccine. The company aims to develop a "Complete Vaccine" that generates a
Vaccines
A groundbreaking coronavirus vaccine, mRNA-1273, developed by Moderna Inc. in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), has demonstrated robust immune responses against SARS-CoV-2 and raised no serious safety concerns in a phase 1 clinical trial. The vaccine, which uses genetic material to produce a protein
Vaccines
Preliminary results from a phase 1 trial of the investigational mRNA-1273 vaccine, designed to protect against SARS-CoV-2, have shown promising results in healthy adults. The vaccine was generally well-tolerated and prompted neutralizing antibody activity, which is essential for preventing the virus from entering human cells. The trial, supported by the
Vaccines
Despite a potentially game-changing COVID-19 vaccine candidate and robust private payroll data, U.S. stocks closed mixed on Wednesday in choppy trading. The Dow Jones Industrial Average dipped 77.91 points to 25,734.97, while the S&P 500 rose 15.57 points to 3,115.86 and
Vaccines
The European Commission has granted marketing authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford. The two-dose vaccine regimen, Zabdeno(R) and Mvabea(R), is designed to induce long-term immunity against the Ebola virus in adults and children aged one year and above.
Coronaviruses
Sanofi, a French pharmaceutical company, has signed a deal with U.S. biotech firm Translate Bio to jointly develop several potential coronavirus vaccines. The partnership involves using messenger ribonucleic acid (mRNA) technology developed by Translate Bio, which instructs cells to produce a key coronavirus protein, triggering an immune response. Sanofi
